Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

SML0572

Sigma-Aldrich

Valspodar

≥98% (HPLC)

Synonym(e):

6-[(2S,4R,6E)-4-Methyl-2-(methylamino)-3-oxo-6-octenoic acid]cyclosporin D, Amdray, PSC833, [3′-Desoxy-3′-oxo-MeBmt]1-[Val]2-cyclosporin

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C63H111N11O12
CAS-Nummer:
121584-18-7
Molekulargewicht:
1214.62
MDL-Nummer:
MFCD00907207
UNSPSC-Code:
12161501
NACRES:
NA.77

Assay

≥98% (HPLC)

Form

powder

Lagerbedingungen

desiccated

Farbe

white to beige

Versandbedingung

wet ice

Lagertemp.

−20°C

InChI

1S/C63H111N11O12/c1-26-27-28-41(16)53(76)52-57(80)67-49(38(10)11)61(84)68(19)33-48(75)69(20)44(29-34(2)3)56(79)66-50(39(12)13)62(85)70(21)45(30-35(4)5)55(78)64-42(17)54(77)65-43(18)58(81)71(22)46(31-36(6)7)59(82)72(23)47(32-37(8)9)60(83)73(24)51(40(14)15)63(86)74(52)25/h26-27,34-47,49-52H,28-33H2,1-25H3,(H,64,78)(H,65,77)(H,66,79)(H,67,80)/b27-26+/t41-,42+,43-,44+,45+,46+,47+,49+,50+,51+,52+/m1/s1

InChIKey

YJDYDFNKCBANTM-QCWCSKBGSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Anwendung

Valspodar/ PSC-833 has been used as a ABCB1 (P-glycoprotein) inhibitor.

Biochem./physiol. Wirkung

Valspodar is a nonimmunosuppressive cyclosporin analog and potent P-glycoprotein (MDR1) inhibitor. Valspodar reverses multidrug resistance (MDR) by inhibiting cellular drug efflux mediated by P-glycoprotein.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 7

1 of 7

Rhodamin 123 BioReagent, for fluorescence, ≥85% (HPLC)

Sigma-Aldrich

83702

Rhodamin 123

Cyclosporin A from Tolypocladium inflatum, BioReagent, for molecular biology, ≥95%

Sigma-Aldrich

C1832

Cyclosporin A

Concanamycin A ≥70% (HPLC)

Sigma-Aldrich

C9705

Concanamycin A

Chinidin anhydrous

Sigma-Aldrich

Q3625

Chinidin

Lucifergelb CH Dilithiumsalz fluorescent stain

Sigma-Aldrich

L0259

Lucifergelb CH Dilithiumsalz

Cyclosporin A from Tolypocladium inflatum, ≥95% (HPLC), solid

Sigma-Aldrich

C3662

Cyclosporin A

Cyclosporin A 97.0-101.5% (on dried basis)

Sigma-Aldrich

30024

Cyclosporin A

Kohjiro Nagao et al.
Biochimica et biophysica acta, 1831(2), 398-406 (2012-11-17)
ATP-binding cassette protein A1 (ABCA1) plays a key role in generating high-density lipoprotein (HDL). However, the detailed mechanism of HDL formation remains unclear; in order to reveal it, chemicals that specifically block each step of HDL formation would be useful.
Benjamin L Emmink et al.
Gastroenterology, 141(1), 269-278 (2011-04-05)
Stem cells of normal tissues have resistance mechanisms that allow them to survive genotoxic insults. The stem cell-like cells of tumors are defined by their tumor-initiating capacity and may have retained these resistance mechanisms, making them resistant to chemotherapy. We
Lynae M Brayboy et al.
Fertility and sterility, 100(5), 1428-1435 (2013-08-21)
To determine the multidrug-resistant transporter (MDR) activity in oocytes and their potential role in oocyte susceptibility to chemotherapy. Experimental laboratory study. University and academic center for reproductive medicine. Women with eggs retrieved for intracytoplasmic sperm injection cycles and adult female
Ziyad Binkhathlan et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 81(1), 142-148 (2012-03-01)
Co-administration of P-glycoprotein (P-gp) inhibitors such as cyclosporine A (CyA) and its analogue valspodar with doxorubicin (DOX) can result in diminished clearance of DOX, leading to accentuated toxicity. The purpose of this study was to evaluate whether the effect of
Jonathan E Kolitz et al.
Blood, 116(9), 1413-1421 (2010-06-05)
Cancer and Leukemia Group B 19808 (CALGB 19808) is the only randomized trial of a second-generation P-glycoprotein (Pgp) modulator in untreated patients with acute myeloid leukemia (AML) younger than age 60 years. We randomly assigned 302 patients to receive induction
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.